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Oligonucleotide-based therapeutics are an emerging class of
drugs that hold the promise for silencing ‘‘un-druggable’’ targets,
thus creating unique opportunities for innovative medicines. As
opposed to gene therapy, oligonucleotides are considered to be
more akin to small molecule therapeutics because they are small,
completely synthetic in origin, do not integrate into the host gen-
ome, and have a deﬁned duration of therapeutic activity after
which effects recover to baseline. They offer a high degree of
speciﬁcity at the genetic level, thereby reducing off-target effects.
At the same time, they provide a strategy for targeting any gene
in the genome, including transcripts that produce mutated
proteins.
Oligonucleotide-based therapeutics include short interfering
RNA (siRNA), that degrade target mRNA through RISC mediated
RNAi; anti-miRs, that target miRNAs; miRNA mimics, that regu-
late target mRNA; antisense oligonucleotides, that may be work-
ing through RNAseH mediated mRNA decay; mRNA upregulation,
by targeting long non-coding RNAs; and oligonucleotides induced
alternative splicing [1]. All these approaches require some mini-
mal degree of homology at the nucleic acid sequence level for
them to be functional. The different mechanisms of action and
their relevant activity are outlined in Fig. 1. Besides homology,
RNA secondary structure has also been exploited in the case of
ribozymes and aptamers, which act by binding to nucleic acids
or proteins, respectively. While there have been many reports
of gene knockdown and gene modulation in cell lines and mice
with all these methods, very few have advanced to clinical stages.
The main obstacle to date has been the safe and effective intracel-
lular delivery of these compounds in higher species, including
humans. Indeed, their action requires direct interaction withJournal of Hepa
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ro-DNA/RNA within the target cell so even when one solves the
issues of tissue and cellular access, intracellular/intranuclear
location represents yet another barrier to overcome. To date,
hepatic delivery of oligonucleotides has been the area with great-
est progress, and thus we have focused on liver-targeted thera-
peutics that have shown promise at the preclinical and/or
clinical level.
The liver is the largest internal organ in the body, playing a
central role in metabolism, detoxiﬁcation, synthesis, and secre-
tion of major plasma proteins (carrier proteins, coagulation fac-
tors, complement components, hormones, and apolipoproteins),
and iron homeostasis. It is therefore not surprising that a large
number of disease targets reside in the liver where they are sus-
ceptible to modulation by oligonucleotide therapies.Clinical-stage oligonucleotide therapies addressing liver
targets
The number of oligonucleotide therapies targeting liver
expressed targets in clinical trials is growing rapidly. The ﬁrst tri-
als involved antisense MOE/Gapmers; however, they have now
been joined by siRNA, locked nucleic acid (LNAs), and morpholi-
nos. MOE/Gapmers are antisense oligonucleotides with phosp-
horothioate backbone linkages. They have a stretch of
nucleotides with deoxy sugars and the remaining nucleotides
containing an O0-methyl O0-ethyl substitution at the 20 position
(MOE). siRNA are double-stranded RNA molecules that vary in
length from 18 to 30 bp, for therapeutic purposes they are typi-
cally chemically modiﬁed, e.g., with 20O-methyl nucleotides to
increase stability and to limit their immunogenicity. LNAs are
modiﬁed RNA nucleotides with an extra bridge connecting the
20 oxygen and 40 carbon in the ribose sugar that increases the
melting temperature of the molecule. Morpholinos are synthetic
molecules with standard nucleic acid bases bound by morphine
rings instead of deoxyribose, and linked through phosphorami-
dite groups. They act by creating steric hindrance after binding
to the target site in a molecule.
This area of metabolic disease has seen the greatest advances
with multiple compounds in clinical trials in the US and/or Eur-
ope. Gene targets for hyperlipidemia, hypercholesterolemia, and
diabetes have all been well validated as loss of function targets
via human genetic studies. Several oligonucleotide therapeutics
targeting liver expressed gene targets have shown promise in
recent clinical trials (Table 1). Speciﬁcally, in the area of
hypercholesterolemia, several programs are progressing through
clinical trials.13 vol. 59 j 1354–1359
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Fig. 1. Proposed mechanism of action for oligonucleotide based therapeutics. (1) RNase H mediated mRNA decay by antisense molecules in the nucleus; (2) siRNA
mediated target mRNA decay exploiting the naturally occurring RNA induced silencing complex (RISC); (3) inhibitory binding of oligonucleotide based aptamer to target
protein; (4) regulation of mRNA translation mediated by binding of miRNA mimics to miRNA binding sites in target mRNA; (5) anti-miR binding to miRNAs in the
cytoplasm, rendering them ineffective for binding their targets.
JOURNAL OF HEPATOLOGYApolipoprotein B (ApoB) is one of the primary components of
circulating atherogenic lipids. Human genetic studies have shown
that mutations in ApoB, which reduce their afﬁnity for the Low
Density Lipoprotein receptor (LDLR), cause marked hypercholes-
terolemia. Complete loss of function in animal models, however,
results in lower total and low density lipoprotein cholesterol
(LDL-C). While being a genetically validated target, loss of ApoB
has also been associated with on-target liabilities, such as liver
steatosis [2].
Currently, the most clinically advanced oligonucleotide thera-
peutic against a liver gene is an antisense molecule (mipomersen)
targeting ApoB (NCT01414881). In phase 3 trials, mipomersen
was recently shown to lower LDL-C in heterozygous and homozy-
gous familial hypercholesterolemia (FH) patients. In heterozy-
gous FH, mipomersen treatment resulted in a 28% vs. +5%
(p <0.001) reduction of LDL-C with almost half of the patients
(45%) achieving a target LDL-C of <2.6 mmol/L (100 mg/dl) [3].
Of note, however, 10.8% of the patients receiving mipomersen
withdrew from treatment due to adverse effects such as injection
site reactions and liver enzyme elevations, as compared to no
patients in the placebo arm. Mipomersen has been approved by
the FDA, but not the EMA, as a treatment to reduce LDL and total
cholesterol in patients with HoFH. A phase 1 trial with an ApoB
siRNA formulated in a ﬁrst generation lipid nanoparticle (LNP)Journal of Hepatology 2013[4] molecule was carried out by Tekmira Pharmaceuticals; the
trial was halted during dose escalation in 2009 (NCT00927459).
Proprotein convertase subtilisin kexin 9 (PCSK9)was originally
identiﬁed in a human genetic studywhich linked it to severely ele-
vated LDL-C. More speciﬁcally, loss-of-function mutations in
PCSK9 in humans resulted in lower LDL-C levels and protection
from cardiovascular disease [5]. Consistent with this observation,
studies in animalmodels demonstrated that loss of PCSK9, a prote-
ase that physiologically downregulates the LDL receptor (LDLR),
leads to an increase in LDLR levels on the hepatocyte, resulting in
increased LDL-C clearance. The RNAi therapeutic ALN-PCS, target-
ing PCSK9, has been evaluated in a phase 1 clinical study
(NCT01437059) [4,6,7]. It was safe, well-tolerated and showed
dose-dependent reduction in PCSK9 and LDL-C. A similar phase 1
single ascending dose of a LNA targeting PCSK9 by ISIS/BMS was
halted during dose escalation due to safety concerns [8].
Apolipoprotein C-III (ApoC3) is a component of very low den-
sity lipoprotein (VLDL), and is thought to be an active inhibitor of
lipoprotein and hepatic lipases, both of which are involved in the
processing and uptake of triglyceride-rich particles. Mutations
in ApoC3 in humans result in lower circulating triglycerides,
and a lowering risk for the development of cardiovascular disease
[9]. Phase 1 studies of an antisense molecule targeting ApoC3
(ISIS Pharmaceuticals, NCT01529424) have shown promise invol. 59 j 1354–1359 1355
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lowering serum triglycerides. Preclinical data with siRNA targeting
ApoC3 have also shown the expected impact on triglycerides in
hyperlipidemic models [10].
Lipoprotein(a), (Lp(a)) levels are associated with an increased
risk of atherosclerosis, coronary heart disease, heart attack and
stroke [11]. ISIS-APOARx is an antisense drug designed to reduce
Lp(a) in the circulation, and has recently entered phase 1 clinical
trials.
Additional phase 1 programs from ISIS Pharmaceuticals in the
area of diabetes have been reported (but have yet to be pub-
lished), and include antisense compounds targeting protein tyro-
sine phosphatase 1B (PTP1B) (NCT00330330) and glucagon
receptor (GCGR) (NCT005197270). Each of these targets has some
degree of validation in animal models or human genetic studies
for the modulation of diabetes and/or obesity [12–14]. Beyond
metabolic targets, a number of other programs address liver-
expressed genes of pathogenic interest. C-reactive protein (CRP)
is an acute-phase reactant involved in response to inﬂammation.
CRP levels are known to be elevated in cardiovascular disease and
possibly diabetes [15]. ISIS-CRPrx is an antisense molecule target-
ing CRP. The drug was well-tolerated in a phase I trial and is cur-
rently in phase 2 trials in atrial ﬁbrillation and rheumatoid
arthritis (NCT01710852).
ISIS-FXI is another antisense molecule currently in phase 2
(NCT01713361). It inhibits the production of factor XI (FXI) and is
predicted to have anti-thrombotic activity. The preclinical data in
cynomolgus monkeys and phase 1 data in healthy volunteers
showed dose-dependent decreases in FXI [16]. The ongoing phase
2 trial is a comparator-controlled study in patients undergoing knee
replacement surgery/total knee arthroplasty. An aptamer against
factor IXa, a liverproduced coagulation factor,was tested inhumans
for anti-thrombotic activity by Regado Biosciences. RB006 demon-
strated the ability to inhibit plasma factor IX activity in a dose
dependent manner in the phase 1 trial (NCT00932100) [17].
Diseases of protein aggregation are also considered prime can-
didates for intervention by oligonucleotide therapies. Elimination
of the amyloidogenic protein by silencing of the corresponding
transcript can enable clearance of protein aggregates such as
amyloid-like deposits. One such disease, transthyretin (TTR)-
mediated amyloidosis (ATTR) is a life-threatening disorder
caused by the deposition of hepatocyte-derived mutant TTR in
peripheral nerves and heart [18]. Therapies under development
for ATTR have shown promise in pre-clinical models, where treat-
ment has resulted in clear disease regression. Both siRNA and
antisense approaches are being investigated in clinical studies
for the treatment of ATTR, including ALN-TTR02 from Alnylam
(NCT01617967) and ISIS-TTRRx (NCT01737398) from ISIS
[19,20]. In addition to ALN-TTR02, Alnylam is developing
ALN-TTRsc (NCT01814839), a subcutaneously administered RNAi
therapeutic that has also recently entered clinical development.
ALN-TTRsc is a chemically modiﬁed siRNA conjugated to an
N-acetylgalactosamine moiety that helps in liver targeting of
the drug via hepatocyte asialoglycoprotein receptor mediated
uptake and allows for subcutaneous administration.Pre-clinical stage oligonucleotide therapies addressing liver
targets
Along with the oligonucleotides in different stages of clinical tri-
als, there are many other candidates being pursued for different1356 Journal of Hepatology 2013diseases (Table 2). While several of these diseases are caused
by mutations in a single gene, others are not monogenic but
may be mitigated by modulating a single gene product in the
liver. The liver diseases can be inherited or acquired during the
life-span of an individual.Inherited diseases
Alpha-1 antitrypsin (AAT) is an abundant liver-secreted plasma
protein. The primary biological function of this serpin is to inac-
tivate proteases like neutrophil elastase. The Glu-342-Lys point
mutation in AAT leads to misfolded protein that polymerizes
and accumulates in the hepatocyte endoplasmic reticulum, lead-
ing to impaired liver function, ﬁbrosis, cirrhosis, and possibly
liver failure or HCC [21]. An oligonucleotide approach targeting
AAT mRNA should be an efﬁcient and safe way to halt pathogenic
protein production. Consistent with this expectation, both RNAi
therapeutic (ALN-AAT [22]) and antisense (ISIS-AAT [23])
approaches have shown promising results in preclinical models.
Angiopoietin like 3 (ANGPTL3) is a member of the angiopoietin
family of secreted proteins. Its major function appears to be an
inhibitor of both endothelial and lipoprotein lipases. Homozygous
loss of function ANGPTL3 mutations in humans result in profound
lowering of total cholesterol, LDL-C, triglycerides and high density
lipoprotein cholesterol (HDL-C). Gain of function ANGPTL3 muta-
tions in humans result in hyperlipidemia [24]. ALN-ANG, a liver
targeted RNAi therapeutic directed towards ANGPTL3, has demon-
strated the expected lowering of both total cholesterol and triglyc-
erides in pre-clinical models [25]. Antisense compounds targeting
ﬁbroblast growth factor receptor 4 (FGFR4) for obesity and diacyl-
glycerol acyltransferase-2 (DGAT2) for non-alcoholic fatty liver
disease (NASH) are being explored in preclinical studies. An oligo-
nucleotide targeting miR33, being developed by Regulus Thera-
peutics, was shown to increase plasma HDL and lower VLDL
triglycerides in preclinical studies [26,27].
Hepatic porphyrias are a group of rare disorders of the heme
synthesis pathway. Mutations in several enzymes in this pathway
can cause a build-up of pathway intermediates which are toxic.
The ﬁrst enzyme in the pathway, ALAS1, is highly regulated and
is induced in response to low levels of heme in the liver. This
induction leads to ﬂux through the pathway and an increase of
the toxic intermediates, 5-aminolevulinic acid (ALA) and porpho-
bilinogen (PBG). Inhibition of ALAS1 induction in acute intermit-
tent porphyria is a promising strategy that should result in
pathway downregulation and prevention in the buildup of
ALA and PBG. ALN-AS1, a subcutaneously administered RNAi
therapeutic targeting ALAS1, is being developed to treat this
ultra-orphan disease (http://www.alnylam.com/Programs-and-
Pipeline/index.php).
Hemophilia A and B as well as several other rare bleeding dis-
orders are caused by loss of function mutations in various clot-
ting factors, resulting in reduced thrombin generation and
excessive bleeding. There is genetic evidence suggesting that
coinheritance of prothrombotic mutations, which enhance
thrombin production, in hemophilia leads to a less severe bleed-
ing phenotype [28]. ALN-AT3, a subcutaneously administered
RNAi therapeutic targeting antithrombin, leads to correction of
thrombin generation in hemophilia mice [29]. In contradistinc-
tion, an antisense targeting Factor VII (ISIS-FVIIRx) is being devel-
oped by Isis as a treatment for thrombosis in a strategy similar tovol. 59 j 1354–1359
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that described for FXI above (http://www.isispharm.com/
Pipeline/index.htm).
Strategies to increase hepcidin levels are also being explored.
TMPRSS6 is a negative-regulator of hepatocyte hepcidin expres-
sion. ALN-TMP, an RNAi therapeutic [30] being developed by
Alnylam, and an antisense compound from ISIS [31,32] both
downregulate TMPRSS6 expression and increase hepcidin secre-
tion leading to improvement in iron overload in models of hemo-
chromatosis and b-thalassemia intermedia. Targeting TMPRSS6
may also ﬁnd application in other dyserythrpoeitic anemias
where iron overload is a feature.Acquired diseases
The liver is also the central player in iron homeostasis, and offers
targets in the hepcidin pathway for intervention under conditions
of both iron overload and anemia. Upon sensing high iron levels,
hepatocytes synthesize and secrete hepcidin. Hepcidin binds to
ferroportin and reduces the iron efﬂux by macrophages and
enterocytes [33]. In cases of chronic anemia, reduction in hepci-
din can lead to an increase in circulating iron and improved
erythropoiesis. Silencing hepcidin, either directly, or by targeting
a positive regulator of hepcidin, such as transferrin receptor II or
hemojuvelin, has shown promise in preclinical models. These
strategies are being deployed to treat anemia of inﬂammation
by both Isis/Xenon and Alnylam [34] (http://www.xenon-
pharma.com/product-candidates/anemia/).
A known outcome for most chronic liver diseases is hepatocel-
lular carcinoma. Owing to their preferential distribution in the
liver, oligonucleotide therapeutics have therefore been usedTable 1. Oligonucleotide therapeutics in clinical trials.
Disease Targeted gene Targeting agent
Acromegaly Growth hormone receptor antisense
Hepatitis C virus miR-122 LNA-antimir
Hypercholesterolemia ApoB-100 antisense
Hypercholesterolemia ApoB-100 siRNA
Hypercholesterolemia ApoB-100 LNA
Hypertriglyceridemia ApoCIII antisense
Hypercholesterolemia PCSK9 siRNA
Hypercholesterolemia PCSK9 LNA
Inflammatory disorders CRP antisense
Liver cancer KSP/VEGF siRNA
Liver cancer PLK1 siRNA
Liver cancer miR-34 miRNA mimic
Obesity FGFR4 antisense
Thrombosis Factor IXa aptamer
Thrombosis Factor XI antisense
TTR amyloidosis TTR antisense
TTR amyloidosis TTR siRNA
Type 2 diabetes GCCR antisense
Type 2 diabetes PTP-1B antisense
Cushing’s syndrome GCGR antisense
Journal of Hepatology 2013against liver cancer. ALN-VSP, an RNAi therapeutic containing
two encapsulated siRNAs targeting kinesin spindle protein
(KSP) and vascular endothelial growth factor-A (VEGF), is being
developed for both primary and secondary liver cancer. In early
trials, ALN-VSP has been shown to be generally well tolerated
[35]. Of particular note, a complete response (deﬁned per
Response Evaluation Criteria in Solid Tumors) was observed in
one patient with endometrial cancer and multiple hepatic metas-
tases that stopped treatment after 26 months. In addition, pro-
longed disease stabilization for 1–1.5 years was seen in patients
with hepatic and extrahepatic metastases and, in some patients,
there was a substantial decrease in tumor blood ﬂow on DCE-
MRI, consistent with an anti-VEGF effect. Moreover, a 50 RACE
method was utilized on patient tumor biopsy samples to show
that RNAi based cleavage of VEGF was occurring in patients
[22]. In addition to siRNA targets, microRNA mimic strategies
for miR-34 (NCT01829971) and miR-7 have also been proposed
as approaches for hepatocellular cancer (HCC) [36]. TKM-PLK1-
001 is another siRNA based approach, targeting Polo like kinase
I, a major player in cell cycle in phase I trial for solid tumors
(NCT01262235). Early results from the ongoing phase I show that
TKM-PLK1 is generally well-tolerated and 4 patients showed clin-
ical beneﬁt and achieved stable disease.
Amongst infectious agents, hepatitis B and C are the common-
est risk factors for liver cancer. Oligonucleotide therapies that
decrease these viruses would have a direct impact on liver infec-
tion, and reduce the risk of HCC. Hepatitis C virus (HCV) requires
miR-122 for its propagation ([37]); hence inhibition of miR-122,
using a complementary oligonucleotide termed an anti-miR, is
an attractive strategy. Santaris Pharmaceuticals is testing an
LNA-anti-miR (miraversen) for miR122 in a phase 2a clinical trial.Pursued by Latest status
ISIS/Antisense Therapeutics Limited Ph 2 recruiting
Santaris Ph 2 ongoing
ISIS/Genzyme Approved by FDA
Tekmira Ph 1 terminated
Santaris Ph 1 completed
ISIS Ph 2 recruiting
Alnylam/Medicines Company Ph 1 completed
ISIS/BMS Ph 1 halted
ISIS Ph 2 recruiting 
Alnylam Ph 1 completed
Tekmira/Protiva Ph 1 ongoing
miRNA therapeutics Ph 1 recruiting
ISIS/Verva Pharmaceuticals Ph 1 ongoing
Regado Biosciences Ph 2a completed
ISIS Ph 2 recruiting
ISIS/GSK Ph 3 recruiting
Alnylam Ph 2 recruiting
ISIS Ph 1 ongoing
ISIS Ph 1 completed
ISIS Ph 1 ongoing
vol. 59 j 1354–1359 1357
Table 2. Preclinical oligonucleotide based therapeutics.
Disease Targeted gene Targeting agent Pursued by Latest status
AAT-LivD AAT siRNA or antisense Alnylam Presented, active
AAT siRNA or antisense  ISIS/GSK Presented, active
Alcohol dependence ALDH2 siRNA Tekmira Announced on website
Anemia of inflammation/
CKD
HAMP pathway siRNA Alnylam Presented, inactive
Atherosclerosis miR-33 anti-miR Regulus/AstraZeneca Presented, active
Atherosclerosis/high 
Lp(a)
ApoAI antisense ISIS Announced on website
Liver cancer miR-7 miRNA-mimic for EGFR MiReven/Silence Presented, inactive
Cardiometabolic 
diseases
miR-378 miR mimic Miragen Therapeutics Announced on website
Liver cancer miR-21 anti-miR (ss) Regulus/Sanofi Presented, active
Liver cancer Myc siRNA Dicerna Presented, active
Hepatitis C virus miR-122 anti-miR (ss) Regulus/GSK Presented, active
Hepatitis C virus 5’UTR ribozyme Sirna/Eli Lilly Presented, inactive
Hepatitis C virus 5’UTR and NS5B shRNA against 3 regions Tacere Therapeutics Presented, active
Hepatitis C virus NS3 aptamer Umehara et al[39] Publication
Hemochromatosis TMPRSS6 siRNA Alnylam Presented, active
Hemophilia A, B Antithrombin III siRNA Alnylam Presented, active
Hypertriglyceridemia ApoCIII siRNA Alnylam Presented, inactive
Hyperlipidemia ANGPLT3 siRNA or antisense Alnylam Presented, inactive
Hyperlipidemia MTP antisense ISIS Publication-Preclin
NASH DGAT2 antisense ISIS Presented, active
Porphyria ALAS1 siRNA Alnylam Presented, active
Rare bleeding disorders Antithrombin III siRNA Alnylam Presented, active
SAA-amyloidosis Serum amyloid A siRNA or antisense Alnylam, ISIS Preclinical
Thrombosis Factor VII antisense ISIS Presented, inactive
AAT-LivD
Clinical Application of Basic ScienceThe results show that a 4-week monotherapy with the anti-miR
reduces HCV RNA by 2–3 logs [38]. In this study, 4 of 9 patients
at the high dose group of 7 mg/kg showed a decrease in HCV lev-
els below the limit of detection.Conclusions
In 1998, the intravitreally-administered antisense molecule,
fomivirsen, for the treatment of cytomegalovirus retinitis, was
the ﬁrst oligonucleotide drug to be approved by the FDA
(NCT00002356). The ﬁrst human oligonucleotide therapeutics
trials involving systemic delivery were published in 1998. In this
clinical trial, an antisense oligodeoxynucleotide against ICAM-1
was delivered via 13 intravenous doses over 26 days in steroid-
treated Crohn’s disease patients (NCT00048113). The drug was
found to be generally safe and well tolerated but did not show
efﬁcacy in a dose-responsive manner. Since that time, tremen-
dous progress has been made, culminating in the recent approval
of the ﬁrst systemically delivered oligonucleotide, mipomersen,
for the treatment of hypercholesterolemia. Improvements in oli-
gonucleotide delivery, increased stability of the molecules, and
decreased toxicity have led to the generation of several new clas-
ses of oligonucleotide based therapies. With well over a dozen
different targets being pursued using a variety of oligonucleotide
therapeutic compounds (siRNA, antisense, anti-miRNA, miRNA1358 Journal of Hepatology 2013mimics) the future has never looked brighter for these disease-
modifying modalities.
Key Points
• Oligonucleotide-based therapies enable targeting and
knockdown of targets that were previously considered
undruggable
• The development of oligonucleotide therapeutics 
targeting hepatocyte-expressed genes is progressing
rapidly
• There is currently a large and growing pipeline of 
therapeutics, with the first systemic oligonucleotide
therapy recently approved by the FDA
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